BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jakimovski D, Weinstock-Guttman B, Ramanathan M, Dwyer MG, Zivadinov R. Infections, Vaccines and Autoimmunity: A Multiple Sclerosis Perspective. Vaccines (Basel) 2020;8:E50. [PMID: 32012815 DOI: 10.3390/vaccines8010050] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 7.0] [Reference Citation Analysis]
Number Citing Articles
1 Severa M, Farina C, Salvetti M, Coccia EM. Three Decades of Interferon-β in Multiple Sclerosis: Can We Repurpose This Information for the Management of SARS-CoV2 Infection? Front Immunol 2020;11:1459. [PMID: 32655578 DOI: 10.3389/fimmu.2020.01459] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Trend S, Leffler J, Teige I, Frendéus B, Kermode AG, French MA, Hart PH. FcγRIIb Expression Is Decreased on Naive and Marginal Zone-Like B Cells From Females With Multiple Sclerosis. Front Immunol 2020;11:614492. [PMID: 33505402 DOI: 10.3389/fimmu.2020.614492] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Jakimovski D, Awan S, Eckert SP, Farooq O, Weinstock-Guttman B. Multiple Sclerosis in Children: Differential Diagnosis, Prognosis, and Disease-Modifying Treatment. CNS Drugs 2021. [PMID: 34940954 DOI: 10.1007/s40263-021-00887-w] [Reference Citation Analysis]
4 Sadeghmousavi S, Rezaei N. COVID-19 and Multiple Sclerosis: Predisposition and Precautions in Treatment. SN Compr Clin Med 2020;:1-6. [PMID: 32895640 DOI: 10.1007/s42399-020-00504-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 7.5] [Reference Citation Analysis]
5 Jakimovski D, Weinstock-Guttman B. Asymptomatic infection after BNT162b2 mRNA COVID-19 vaccination in multiple sclerosis patient. Acta Neurol Belg 2022;122:565-6. [PMID: 34529258 DOI: 10.1007/s13760-021-01799-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Jakimovski D, Eckert SP, Zivadinov R, Weinstock-Guttman B. Considering patient age when treating multiple sclerosis across the adult lifespan. Expert Rev Neurother 2021;21:353-64. [PMID: 33595379 DOI: 10.1080/14737175.2021.1886082] [Reference Citation Analysis]
7 Kristensen MK, Christensen T. Regulation of the expression of human endogenous retroviruses: elements in fetal development and a possible role in the development of cancer and neurological diseases. APMIS 2021;129:241-53. [PMID: 33683784 DOI: 10.1111/apm.13130] [Reference Citation Analysis]
8 Otero-Romero S, Ascherio A, Lebrun-Frénay C. Vaccinations in multiple sclerosis patients receiving disease-modifying drugs. Curr Opin Neurol 2021;34:322-8. [PMID: 33709979 DOI: 10.1097/WCO.0000000000000929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
9 Boyko AN, Sivertseva SA, Chemakina DS, Spirin NN, Bykova OV, Guseva ME. [Vaccination and multiple sclerosis at the present stage]. Zh Nevrol Psikhiatr Im S S Korsakova 2021;121:44-8. [PMID: 34387445 DOI: 10.17116/jnevro202112107244] [Reference Citation Analysis]
10 Kammona O, Kiparissides C. Recent Advances in Antigen-Specific Immunotherapies for the Treatment of Multiple Sclerosis. Brain Sci 2020;10:E333. [PMID: 32486045 DOI: 10.3390/brainsci10060333] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
11 Li J, Wu DM, Yu Y, Deng SH, Liu T, Zhang T, He M, Zhao YY, Xu Y. Amifostine ameliorates induction of experimental autoimmune encephalomyelitis: Effect on reactive oxygen species/NLRP3 pathway. Int Immunopharmacol 2020;88:106998. [PMID: 33182064 DOI: 10.1016/j.intimp.2020.106998] [Reference Citation Analysis]
12 Jakimovski D, Vaughn CB, Eckert S, Zivadinov R, Weinstock-Guttman B. Long-term drug treatment in multiple sclerosis: safety success and concerns. Expert Opin Drug Saf 2020;19:1121-42. [PMID: 32744073 DOI: 10.1080/14740338.2020.1805430] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li Y, Xiao Y, Chen Y, Huang K. Nano-based approaches in the development of antiviral agents and vaccines. Life Sci 2021;265:118761. [PMID: 33189824 DOI: 10.1016/j.lfs.2020.118761] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
14 Principi N, Esposito S. Do Vaccines Have a Role as a Cause of Autoimmune Neurological Syndromes? Front Public Health 2020;8:361. [PMID: 32850592 DOI: 10.3389/fpubh.2020.00361] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
15 Maple PAC. Multiple Sclerosis, Viruses, and New Vaccines. Neurol Int 2021;13:712-4. [PMID: 34940754 DOI: 10.3390/neurolint13040068] [Reference Citation Analysis]
16 Tornatore C, Wiendl H, Lublin AL, Geertsen SS, Chavin J, Truffinet P, Bar-or A. Vaccine Response in Patients With Multiple Sclerosis Receiving Teriflunomide. Front Neurol 2022;13:828616. [DOI: 10.3389/fneur.2022.828616] [Reference Citation Analysis]